Clinical Trial

A Study of BGM0504 in Participants With Obesity

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 28, 2025 (before its estimated January 11, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-03; most recent amendment 2025-10-27.
Trial Details
NCT Number NCT06911203
Lead Sponsor BrightGene Bio-Medical Technology Co., Ltd.
Conditions Obesity
Enrollment 90 participants
Start Date 2025-04-03
Primary Completion 2026-01-11 (estimated)
Study Completion 2026-01-11 (estimated)
Updated on ClinicalTrials.gov 2025-10-28